Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone

Clifford J. Bailey; Brian D. Green; Peter R. Flatt

doi:10.1517/13543784.2010.505235

Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone

Clifford J. Bailey, Brian D. Green, Peter R. Flatt

Research output: Contribution to journal › Article › peer-review

Abstract

Type 2 diabetes is typically associated with insulin resistance and dysfunction of insulin-secreting pancreatic beta-cells. Addressing these defects often requires therapy with a combination of differently acting antidiabetic agents. A potential novel combination in development brings together the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin with the thiazolidinedione pioglitazone into a fixed-dose single-tablet combination. The former component acts mainly to increase prandial insulin secretion; the latter improves insulin sensitivity.

Original language	English
Pages (from-to)	1017-1025
Number of pages	9
Journal	Expert Opinion on Investigational Drugs: authoritative analysis of r and d trends
Volume	19
Issue number	8
DOIs	https://doi.org/10.1517/13543784.2010.505235
Publication status	Published - Aug 2010

Keywords

Animals
Clinical Trials as Topic
Diabetes Mellitus, Type 2
Dipeptidyl-Peptidase IV Inhibitors
Drug Therapy, Combination
Female
Humans
Hypoglycemia
Hypoglycemic Agents
Insulin Resistance
Male
Pyrazines
Thiazolidinediones
Triazoles

Access to Document

10.1517/13543784.2010.505235

Link to publication in Scopus

Fingerprint Dive into the research topics of 'Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone'. Together they form a unique fingerprint.

Cite this

@article{1a1de0ecb5e2462580e0d4a697ad7bfe,

title = "Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone",

abstract = "Type 2 diabetes is typically associated with insulin resistance and dysfunction of insulin-secreting pancreatic beta-cells. Addressing these defects often requires therapy with a combination of differently acting antidiabetic agents. A potential novel combination in development brings together the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin with the thiazolidinedione pioglitazone into a fixed-dose single-tablet combination. The former component acts mainly to increase prandial insulin secretion; the latter improves insulin sensitivity.",

keywords = "Animals, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Drug Therapy, Combination, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin Resistance, Male, Pyrazines, Thiazolidinediones, Triazoles",

author = "Bailey, {Clifford J.} and Green, {Brian D.} and Flatt, {Peter R.}",

year = "2010",

month = aug,

doi = "10.1517/13543784.2010.505235",

language = "English",

volume = "19",

pages = "1017--1025",

journal = "Expert Opinion on Investigational Drugs: authoritative analysis of r and d trends ",

issn = "1354-3784",

publisher = "Informa Healthcare",

number = "8",

}

TY - JOUR

T1 - Fixed-dose combination therapy for type 2 diabetes

T2 - sitagliptin plus pioglitazone

AU - Bailey, Clifford J.

AU - Green, Brian D.

AU - Flatt, Peter R.

PY - 2010/8

Y1 - 2010/8

N2 - Type 2 diabetes is typically associated with insulin resistance and dysfunction of insulin-secreting pancreatic beta-cells. Addressing these defects often requires therapy with a combination of differently acting antidiabetic agents. A potential novel combination in development brings together the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin with the thiazolidinedione pioglitazone into a fixed-dose single-tablet combination. The former component acts mainly to increase prandial insulin secretion; the latter improves insulin sensitivity.

AB - Type 2 diabetes is typically associated with insulin resistance and dysfunction of insulin-secreting pancreatic beta-cells. Addressing these defects often requires therapy with a combination of differently acting antidiabetic agents. A potential novel combination in development brings together the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin with the thiazolidinedione pioglitazone into a fixed-dose single-tablet combination. The former component acts mainly to increase prandial insulin secretion; the latter improves insulin sensitivity.

KW - Animals

KW - Clinical Trials as Topic

KW - Diabetes Mellitus, Type 2

KW - Dipeptidyl-Peptidase IV Inhibitors

KW - Drug Therapy, Combination

KW - Female

KW - Humans

KW - Hypoglycemia

KW - Hypoglycemic Agents

KW - Insulin Resistance

KW - Male

KW - Pyrazines

KW - Thiazolidinediones

KW - Triazoles

UR - http://www.scopus.com/inward/record.url?scp=77954713342&partnerID=8YFLogxK

U2 - 10.1517/13543784.2010.505235

DO - 10.1517/13543784.2010.505235

M3 - Article

C2 - 20629618

VL - 19

SP - 1017

EP - 1025

JO - Expert Opinion on Investigational Drugs: authoritative analysis of r and d trends

JF - Expert Opinion on Investigational Drugs: authoritative analysis of r and d trends

SN - 1354-3784

IS - 8

ER -